News | May 19, 2009

Invatec Launches Coronary Drug-Eluting Balloon Platform IN.PACT Falcon at EuroPCR

The first photo shows a control in a porcine artery treated with a conventional uncoated balloon, showing massive neointimal proliferation. The second photo shows a different section of the same artery treated with a IN.PACT paclitaxel-coated balloon.

May 19, 2009 - Invatec announced today the availability of its newly CE-marked coronary balloon, the IN.PACT Falcon paclitaxel-eluting PTCA balloon catheter at the EuroPCR Congress 2009 in Barcelona, Spain.

This is one of the first drug-eluting balloons released in Europe designed specifically to treat atherosclerosis in the coronary arteries and underscores Invatec’s commitment to robust scientific research into the reduction of re-intervention rates in the treatment of coronary artery disease (CAD). The IN.PACT Falcon is not FDA-cleared.

“Combining world-class PTCA balloon catheter technology with local drug administration is a fascinating new concept for the treatment of certain coronary lesions such as in-stent restenosis (ISR), small vessel disease (SVD), bifurcations and potentially other lesions where conventional balloons, stents and even drug eluting stents may not be ideal,” said Professor Eberhard Grube, chief, department of cardiology/angiology at The Heart Center, Siegburg, Germany. “A drug eluting balloon such as the IN.PACT Falcon that elutes a known and effective drug such as paclitaxel holds much promise as an effective treatment option for patients.”

IN.PACT Falcon combines the currently marketed, performance-leading Falcon line of PTCA balloon catheters with Invatec’s proprietary IN.PACT technology platform and FreePac coating. FreePac is a proprietary, natural coating that frees and separates paclitaxel molecules and facilitates their absorption into the wall of the artery. The FreePac coating was developed in close collaboration with the researchers who pioneered drug-eluting balloon therapy, Ulrich Speck, Ph.D., department of radiology at Charite Mitte, Berlin and Bruno Scheller, M.D., University Hospital, department of internal medicine, Homburg/Saar.

For more information: visit

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init